{"id":11409,"date":"2025-07-26T20:29:04","date_gmt":"2025-07-26T18:29:04","guid":{"rendered":"https:\/\/valintermed.com\/?p=11409"},"modified":"2025-07-26T20:29:04","modified_gmt":"2025-07-26T18:29:04","slug":"reaktsiya-transplantat-protiv-hozyaina-rtph","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/transplant-reaction-against-owner-rtph\/","title":{"rendered":"Graft-versus-host disease (GVHD)"},"content":{"rendered":"<div class=\"fpm_start\"><\/div>\n<p>Graft-versus-host disease (GVHD) is a serious complication that can occur after allogeneic transplantation of cells or organs, particularly bone marrow. This condition occurs when the donor&#039;s immune cells recognize the recipient&#039;s tissues as foreign and begin to attack them. GVHD can manifest itself with a variety of systemic symptoms, including dermatological lesions, liver damage, intestinal damage, and other organs. This disorder, characterized by a reaction of the immune system, has attracted considerable interest in clinical practice because of its potentially life-threatening consequences and the difficulty of treatment.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_86 counter-flat ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Content<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 eztoc-toggle-hide-by-default' ><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/transplant-reaction-against-owner-rtph\/#%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\" >History of the disease and interesting historical facts<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/transplant-reaction-against-owner-rtph\/#%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F\" >Epidemiology<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/transplant-reaction-against-owner-rtph\/#%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E\" >Genetic predisposition to this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/transplant-reaction-against-owner-rtph\/#%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Risk factors for the development of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/transplant-reaction-against-owner-rtph\/#%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Diagnosis of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/transplant-reaction-against-owner-rtph\/#%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\" >Treatment<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/transplant-reaction-against-owner-rtph\/#%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >List of medications used to treat this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/transplant-reaction-against-owner-rtph\/#%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Disease monitoring<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/transplant-reaction-against-owner-rtph\/#%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Age-related features of the disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/transplant-reaction-against-owner-rtph\/#%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\" >Questions and Answers<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/transplant-reaction-against-owner-rtph\/#%D0%A1%D0%BE%D0%B2%D0%B5%D1%82%D1%8B_%D0%BE%D1%82_%D0%B4%D0%BE%D0%BA%D1%82%D0%BE%D1%80%D0%B0_%D0%9E%D0%BB%D0%B5%D0%B3%D0%B0_%D0%9A%D0%BE%D1%80%D0%B6%D0%B8%D0%BA%D0%BE%D0%B2%D0%B0\" >Advice from Dr. Oleg Korzhikov<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\"><\/span>History of the disease and interesting historical facts<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>GVHD was first described in 1959 when researchers found that patients who had received allogeneic transplants were experiencing various complications associated with a high degree of immune reaction. Since then, the study of this condition has become an important part of transplantation. One of the most notable historical facts is that GVHD was first seen in patients with leukemia, but it was later found that it could also develop in other conditions, such as bone marrow failure and various genetic diseases. Research in the field of GVHD has demonstrated the importance of paying attention to immunological aspects and taking into account genetic differences between donor and recipient.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F\"><\/span>Epidemiology<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>According to various studies, the incidence of GVHD varies depending on the type of transplant and the method of its collection. Taking into account the results of clinical observations, the following statistical data can be highlighted:<\/p>\n<ul>\n<li>GVHD develops in 30-50% patients receiving allogeneic blood cell transplants for acute leukemia.<\/li>\n<li>The pathology is also observed in 10-30% patients who have undergone bone marrow transplantation from unrelated donors.<\/li>\n<li>In patients who have received organ transplants such as liver or kidney, the incidence of GVHD remains much lower, at approximately 5%.<\/li>\n<\/ul>\n<p>These data highlight the high susceptibility of patients with certain blood disorders to this condition.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E\"><\/span>Genetic predisposition to this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Genetic predisposition to GVHD plays an important role in its development. Research points to several key genes and mutations that may increase the risk of this condition:<\/p>\n<ul>\n<li>Genes responsible for antigen markers of the major histocompatibility complex (HLA) play a key role in determining compatibility between donor and recipient.<\/li>\n<li>Polymorphisms of genes associated with immune response, such as IL-10, TNF-\u03b1 and IFN-\u03b3, are also important.<\/li>\n<li>Current research suggests that specific genetic variations may increase the risk of developing acute forms of GVHD.<\/li>\n<\/ul>\n<p>These data are important for developing personalized approaches to treatment and prevention of the disease.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Risk factors for the development of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>There are several risk factors that contribute to the development of GVHD, which can be classified as physical and chemical:<\/p>\n<ul>\n<li>Physical:\n<ul>\n<li>Recipient age: Increasing age is associated with increased risk.<\/li>\n<li>Gender: Men are at higher risk than women.<\/li>\n<li>Graft type: A higher incidence of GVHD is observed with transplants from fragments and unrelated donors.<\/li>\n<\/ul>\n<\/li>\n<li>Chemicals:\n<ul>\n<li>Use of immunosuppressive drugs to prevent transplant rejection.<\/li>\n<li>Radiation therapy and chemotherapy may also predispose to the development of GVHD.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>Also, socioeconomic factors and underlying medical conditions may increase the risk of developing this condition.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Diagnosis of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Diagnosis of GVHD includes several stages:<\/p><script data-noptimize=\"\" data-wpfc-render=\"false\">\nfpm_start( \"true\" );\n<\/script>\n\n<ul>\n<li>Main symptoms:\n<ul>\n<li>Dermatological manifestations: itching, rash, eczema.<\/li>\n<li>Geo-ratio hepatitis: jaundice, enlarged liver.<\/li>\n<li>Dyspepsia and diarrhea: frequent and loose stools, abdominal pain.<\/li>\n<\/ul>\n<\/li>\n<li>Laboratory tests:\n<ul>\n<li>Blood test for transaminase levels and other biochemical liver parameters.<\/li>\n<li>Hematological tests to assess the state of the immune system.<\/li>\n<\/ul>\n<\/li>\n<li>Radiological examinations:\n<ul>\n<li>Ultrasound examination of the liver and abdominal organs.<\/li>\n<li>CT scan of the lungs to detect pneumonia and other pulmonary complications.<\/li>\n<\/ul>\n<\/li>\n<li>Differential diagnosis:\n<ul>\n<li>The need to exclude other conditions such as infections, acute inflammatory diseases, allergic reactions.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>Timely diagnosis is necessary to prescribe adequate treatment.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\"><\/span>Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Treatment of GVHD includes several approaches depending on the severity of the condition:<\/p>\n<ul>\n<li>General treatment:\n<ul>\n<li>The use of immunosuppressive therapy to reduce the activity of the immune response.<\/li>\n<li>Maintenance therapy to control symptoms such as itching or diarrhea.<\/li>\n<\/ul>\n<\/li>\n<li>Pharmacological treatment:\n<ul>\n<li>Immunosuppressants such as methotrexate and cyclosporine.<\/li>\n<li>Corticosteroids to reduce inflammation.<\/li>\n<\/ul>\n<\/li>\n<li>Surgical treatment:\n<ul>\n<li>In rare cases, surgery may be required to correct severe organ damage.<\/li>\n<\/ul>\n<\/li>\n<li>Other types of treatment:\n<ul>\n<li>Plasmapheresis to remove elevated levels of antibodies from the bloodstream.<\/li>\n<li>The use of experimental methods such as cell therapy.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>An integrated approach to treatment helps to increase survival rates and improve the quality of life of patients.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>List of medications used to treat this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The main drugs used to treat GVHD include:<\/p>\n<ul>\n<li>Methotrexate<\/li>\n<li>Cyclosporine<\/li>\n<li>Tacrolimus<\/li>\n<li>Corticosteroids (prednisolone, methylprednisolone);<\/li>\n<li>Tocoida immunoglobulins<\/li>\n<\/ul>\n<p>These drugs help reduce the activity of the immune response and alleviate the clinical manifestations of the disease.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Disease monitoring<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Control and monitoring of GVHD should be carried out at all stages and include:<\/p>\n<ul>\n<li>Control stages:\n<ul>\n<li>Regular monitoring of laboratory test results.<\/li>\n<li>Assessment of the condition of organs (liver, skin, intestines) in dynamics.<\/li>\n<\/ul>\n<\/li>\n<li>Forecast:\n<ul>\n<li>The prognosis depends on the severity of GVHD and the adequacy of treatment.<\/li>\n<li>Moderate forms of GVHD often have a better prognostic picture compared to severe ones.<\/li>\n<\/ul>\n<\/li>\n<li>Complications:\n<ul>\n<li>Serious complications such as infections and delayed organ reactions are possible.<\/li>\n<li>Long-term consequences may include chronic disease and the need for repeat transplants.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>Regular monitoring of the condition helps to avoid serious complications and improve the outcome of treatment.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Age-related features of the disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>GVHD manifests itself differently in different age groups. In childhood, the disease may have a more aggressive course and is more often associated with acute forms, while in older patients, symptoms may be less pronounced, but the risk of complications is increased. These differences require a specific approach to diagnosis and treatment at each stage of life, taking into account age-related features.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\"><\/span>Questions and Answers<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>What are the symptoms of GVHD?<\/strong> Symptoms may include skin rashes, jaundice, gastrointestinal disturbances such as diarrhea and abdominal pain.<\/li>\n<li><strong>What is the cause of GVHD?<\/strong> The main reason is the immune response of donor cells to foreign tissues of the recipient, caused by genetic and antigenic differences.<\/li>\n<li><strong>How dangerous is GVHD?<\/strong> GVHD can have serious health consequences, including damage to vital organs and high mortality without adequate treatment.<\/li>\n<li><strong>What are the main treatments for GVHD?<\/strong> Treatment includes immunosuppressive drugs, corticosteroids, and supportive care depending on the severity of the condition.<\/li>\n<li><strong>Can GVHD be prevented?<\/strong> Complete prevention is not possible, but the use of appropriate immunosuppressive methods and careful donor selection can reduce the risk.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A1%D0%BE%D0%B2%D0%B5%D1%82%D1%8B_%D0%BE%D1%82_%D0%B4%D0%BE%D0%BA%D1%82%D0%BE%D1%80%D0%B0_%D0%9E%D0%BB%D0%B5%D0%B3%D0%B0_%D0%9A%D0%BE%D1%80%D0%B6%D0%B8%D0%BA%D0%BE%D0%B2%D0%B0\"><\/span>Advice from Dr. Oleg Korzhikov<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dr. Oleg Korzhikov recommends that patients with GVHD strictly follow treatment regimens and undergo regular follow-up examinations. It is important to lead a healthy lifestyle, avoid stress, and monitor nutrition, especially dietary supplements and pharmacological agents. \u201cDon\u2019t forget to inform your doctor about any new symptoms and side effects in order to adjust the treatment,\u201d the specialist advises.<\/p>\n<div class=\"fpm_end\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Graft-versus-host disease (GVHD) is a serious complication that can occur after allogeneic transplantation of cells or organs, particularly bone marrow.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[298],"tags":[],"class_list":["post-11409","post","type-post","status-publish","format-standard","hentry","category-medlibrary"],"_links":{"self":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/11409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/comments?post=11409"}],"version-history":[{"count":1,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/11409\/revisions"}],"predecessor-version":[{"id":15806,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/11409\/revisions\/15806"}],"wp:attachment":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media?parent=11409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/categories?post=11409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/tags?post=11409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}